



# A proposed lung ultrasound and phenotypic algorithm for the care of COVID-19 patients with acute respiratory failure

## Proposition d'un algorithme basé sur l'échographie pulmonaire et le phénotype physiologique pour la prise en charge des patients atteints de la COVID-19 souffrant d'insuffisance respiratoire aiguë

André Y. Denault, MD, PhD, FRCPC, FASE, FCCSm, ABIM-CCM · Stéphane Delisle, PhD, RRT, FCCM · David Canty, MBBS, MD, PhD, FANZCA · Alistair Royse, MBBS, MD, FRACS, FCSANZ · Colin Royse, MBBS, MD, FANZCA · Ximena Cid Serra, MD · Caroline E. Gebhard, MD · Étienne J. Couture, MD, FRCPC · Martin Girard, MD, FRCPC · Yiorgos Alexandros Cavayas, MD, MSc, FRCPC · Nicolas Peschanski, MD, PhD · Stéphan Langevin, MD, FRCPC · Paul Ouellet, PhD, RRT, FCCM

Received: 21 April 2020/Revised: 30 April 2020/Accepted: 4 May 2020/Published online: 21 May 2020  
© Canadian Anesthesiologists' Society 2020

**Abstract** Pulmonary complications are the most common clinical manifestations of coronavirus disease (COVID-19). From recent clinical observation, two phenotypes have emerged: a low elastance or L-type and a high elastance or H-type. Clinical presentation, pathophysiology, pulmonary mechanics, radiological and ultrasound findings of these two phenotypes are different. Consequently, the

therapeutic approach also varies between the two. We propose a management algorithm that combines the respiratory rate and oxygenation index with bedside lung ultrasound examination and monitoring that could help determine earlier the requirement for intubation and other surveillance of COVID-19 patients with respiratory failure.

**Résumé** Les complications pulmonaires du coronavirus (COVID-19) constituent ses manifestations cliniques les plus fréquentes. De récentes observations cliniques ont fait émerger deux phénotypes : le phénotype à élastance faible

**Electronic supplementary material** The online version of this article (<https://doi.org/10.1007/s12630-020-01704-6>) contains supplementary material, which is available to authorized users.

A. Y. Denault, MD, PhD, FRCPC, FASE, FCCSm, ABIM-CCM (✉)  
Division of Critical Care, Centre Hospitalier de l'Université  
Montréal, Montreal, QC, Canada  
e-mail: andre.denault@umontreal.ca

Department of Anesthesiology and Critical Care Division,  
Montreal Heart Institute, Université de Montréal, 5000 Belanger  
Street, Montreal, QC, Canada HIT 1C8

S. Delisle, PhD, RRT, FCCM  
Département de médecine de famille et médecine d'urgence,  
Université de Montréal, Montreal, QC, Canada

Collège Ellis, Trois-Rivières, QC, Canada

D. Canty, MBBS, MD, PhD, FANZCA  
Department of Surgery, University of Melbourne, Melbourne,  
Australia

Department of Anaesthesia and Pain Management, Royal  
Melbourne Hospital, Melbourne, Australia

Department of Medicine, Monash University, Melbourne,  
Australia

Department of Anaesthesia and Perioperative Medicine, Monash  
Health, Melbourne, Australia

A. Royse, MBBS, MD, FRACS  
Department of Surgery, University of Melbourne, Melbourne,  
Australia

Cardiothoracic Surgeon, Royal Melbourne Hospital, Melbourne,  
Australia

C. Royse, MBBS, MD, FANZCA  
Department of Surgery, University of Melbourne, Melbourne,  
Australia

*ou type L (low), et le phénotype à élastance élevée, ou type H (high). La présentation clinique, la physiopathologie, les mécanismes pulmonaires, ainsi que les observations radiologiques et échographiques de ces deux différents phénotypes sont différents. L'approche thérapeutique variera par conséquent selon le phénotype des patients atteints de COVID-19 souffrant d'insuffisance respiratoire.*

**Keywords** COVID-19 · lung ultrasound · respiratory failure · respiratory rate · and oxygenation index

The coronavirus disease (COVID-19) first emerged in December 2019 in Wuhan, Hubei Province, China. The infection, caused by severe acute respiratory syndrome coronavirus 2 quickly propagated, eventually leading to the pandemic now affecting most countries around the world.<sup>1</sup> The viral pneumonia caused by COVID-19 was initially reported in China to be associated with a mortality rate of 1.4%.<sup>2</sup> Higher mortality rates have been reported in other countries.<sup>3,4</sup> Initial reports on the pulmonary manifestation of COVID-19 described abnormalities observed on computed tomography (CT) in up to 86.2% of patients who presented for acute care and in 94.6% of those with severe disease.<sup>2,5</sup> These manifestations consist of ground-glass opacities, local and bilateral patchy shadowing, and interstitial abnormalities.<sup>5</sup> Abnormalities were also observed on chest radiography, such as bilateral peripheral consolidation and ground-glass opacities,<sup>6</sup> as well with the use of lung ultrasound.<sup>7-10</sup>

Royal Melbourne Hospital, Melbourne, Australia

Outcomes Research Consortium, Cleveland Clinic, Cleveland, USA

X. C. Serra, MD  
Department of Surgery, University of Melbourne, Melbourne, Australia

C. E. Gebhard, MD  
Department of Intensive Care Medicine, University Hospital Basel, Basel, Switzerland

É. J. Couture, MD, FRCPC · S. Langevin, MD, FRCPC  
Department of Anesthesiology and Department of Medicine, Division of Intensive Care Medicine, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, QC, Canada

Université Laval, Québec, QC, Canada

M. Girard, MD, FRCPC  
Department of Anesthesiology and Division of Critical Care, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada

## Two phenotypes for one pathophysiology

Two phenotypes have recently been suggested to describe the clinical features of respiratory failure in COVID-19—a low elastance (L-type) phenotype and a high elastance (H-type) phenotype.<sup>11-13</sup> As the elastance is the inverse of the compliance, the L-type indicates high compliance, and the H-type the opposite. The phenotype's differing presentations are based on viral load timing, comorbidities, and likely genetic determinants of the response to hypoxemia.<sup>13</sup> The L-type is the most common phenotype (> 50%).<sup>13</sup> Those patients present with hypoxemia and hypocapnia but without dyspnea. They have normal respiratory system mechanics, hence the reported term by several emergency physicians of “happy hypoxic COVID” because, despite significant oxygen desaturation, the patient remains alert and able to talk. While some may keep a normal respiratory drive, others may exhibit a significantly increased respiratory drive, which could induce a patient self-inflicted lung injury (P-SILI).<sup>14-18</sup> Hypoxemia in the L-type phenotype is thought to result from a ventilation-perfusion mismatch and loss of hypoxic vasoconstriction leading to shunt fraction up to 50%.<sup>11</sup> As reported in the acute respiratory system (ARDS), the severity seems to correlate with the difference between the end-tidal carbon dioxide and the arterial partial pressure of carbon dioxide (PaCO<sub>2</sub>), which is an indirect measure of dead-space.<sup>19</sup> The CT and chest radiographs reveal well-aerated compartments, patchy disease and ground-glass opacities with some peripheral involvement.<sup>20</sup>

The high elastance (H-type) is more consistent with a classical picture of ARDS from non-COVID-19 settings. Hypoxemia in those patients is a result of shunting through the consolidated regions of the lung, which is more


Y. A. Cavayas, MD, MSc, FRCPC  
Division of Critical Care, Hôpital Sacré-Coeur de Montréal and Montreal Heart Institute, Université de Montréal, Montreal, QC, Canada

N. Peschanski, MD, PhD  
Emergency Department, University of Rennes 1, Rennes, France

Emergency Physician, University Hospital of Rennes, Rennes, France

P. Ouellet, PhD, RRT, FCCM  
Department of Surgery, Sherbrooke University, Sherbrooke, QC, Canada

Clinical Consultant, Vitalité Health Network, Edmundston, NB, Canada



**Fig. 1** A) Computed tomography scan in a 68-yr-old coronavirus disease (COVID-19) patient with progressive dyspnea and oxygen saturation of 86% on room air. A L-type phenotypic pattern is shown. Lung ultrasound revealed a small right pleural effusion, several anterior subpleural consolidations, and B-lines in the posterior region. While in the intensive care unit, the patient experienced fever and progressive respiratory deterioration requiring intubation after 24 hr. The peripheral pulse oximetry remained at 87% despite a fraction of inspired oxygen ( $F_{iO_2}$ ) at 100%, positive end-expiratory pressure titration of 10  $cmH_2O$ , and inhaled nitric oxide of 10 ppm. Blood gas

revealed a pH of 7.37, partial pressure of carbon dioxide ( $PCO_2$ ) of 43.4 mmHg, and oxygen partial pressure ( $PaO_2$ ) of 63.8 mmHg. After 15 min of prone positioning, the  $SaO_2$  increased to 95% and on the following blood gas assessment, the  $PaO_2/F_{iO_2}$  ratio was 268 with a compliance of 53  $mL \cdot cmH_2O$ . B) A repeat CT scan in the same patient was done on day 4 to rule-out a pulmonary embolism. A transition to the H-type is observed. C) Transition in a 49-yr-old man recovering from COVID-19 respiratory failure. His phenotype changed from an H-type to an (D) L-type (courtesy of Dr. Emmanuel Charbonney and Dr. Lawrence Leroux)

important than in the L-type. As those clinical manifestations are different, the treatment will vary according to the predominant pattern. Notably, a transition from L-type to H-type may evolve because of progression of COVID-19 pneumonia, injurious mechanical ventilation, and/or P-SILI.<sup>14-18</sup> Regression from an H-type to L-type or gradual normalization has also been observed with CT during recovery (Fig. 1).<sup>20,21</sup>

### Proposed management algorithm


Figure 2 outlines a proposed management algorithm for a rational approach to ventilatory support of COVID-19

patients with acute respiratory failure. Although it will need careful prospective clinical evaluation, it can be considered an “outside the box” perspective in this new clinical frontier. Its purpose is to help clarify the importance in ventilation strategies, which will be very different for the two ARDS phenotypes seen in COVID-19.

### Ventilation strategies for different phenotypes

We propose that the algorithm be initiated when oxygen therapy is needed to correct symptomatic hypoxemia in COVID-19 patients with acute respiratory failure—e.g., when hypoxemia occurs that is refractory to oxygen

### Covid-19 Clinical Presentation




**Fig. 2** COVID-19 respiratory failure management. Following clinical and ultrasound examination to determine the L-type (low elastance) or H-type (high elastance) pattern, oxygen therapy is initiated. There can be progression or regression from one type to the other. The respiratory rate and oxygenation (ROX) index can be used, calculated, and monitored along with lung ultrasound to help in the process of deciding if and when to intubate. Mechanical ventilation settings include the tidal volume (TV), the respiratory rate (RR), and the degree of positive end-expiratory pressure (PEEP), which will vary according to the L or H phenotype. \* Indicates that the decision

to intubate is based on oxygenation and ventilation failure or compromised airway patency before initiating mechanical ventilation. ARDS = acute respiratory distress syndrome; CT = computed tomography; ECMO = extracorporeal membrane oxygenation; ETCO<sub>2</sub> = end-tidal carbon dioxide; F<sub>i</sub>O<sub>2</sub> = inspired oxygen; P = pressure; PaO<sub>2</sub> = oxygen partial pressure; PAP = pulmonary artery pressure; PBW = predicted body weight; Pplat = plateau pressure; ROX index; SpO<sub>2</sub> = pulse oxygen saturation; V/Q = ventilation perfusion. Adapted in part from Gattinoni *et al.*<sup>11, 13</sup> and Marini *et al.*<sup>27</sup>

therapy with a high-flow nasal cannula (HFNC) with an increased fraction of inspired oxygen (F<sub>i</sub>O<sub>2</sub>). Traditionally, the response to oxygen therapy is assessed with the oxygen partial pressure (PaO<sub>2</sub>)/F<sub>i</sub>O<sub>2</sub> ratio<sup>22</sup> or alternatively, when using peripheral pulse oximetry (SpO<sub>2</sub>), the SpO<sub>2</sub>/F<sub>i</sub>O<sub>2</sub>.<sup>23</sup> Even though these ratios are well documented, they do not

take into account the underlying respiratory workload. A PaO<sub>2</sub>/F<sub>i</sub>O<sub>2</sub> ≤ 150 mmHg is considered a severe hypoxemic state and mandates close clinical supervision and intervention. The medical community is now supporting the use of HFNC as a clinically accepted adjunct approach to treating hypoxemia in COVID-19 patients.<sup>24</sup> The






**Fig. 3** COVID-19 lung ultrasound findings. (A) B-lines (arrow); (B) irregular and broken pleural lines with multiple B-lines (dotted region); (C) peripheral or subpleural consolidation with (D) minimal colour Doppler signal. (E) Larger zone of consolidation in right lower

posterior base with air bronchograms and (F) reduced perfusion using colour Doppler. (Courtesy of Dr. Stéphan Langevin and Dr. Caroline Gebhard) (Videos 3A, 3B, 3C, 3D, 3E, and 3F available as Electronic Supplementary Material)

literature from HFNC technology proposes a novel index, validated as a prognostic outcome of short-term HFNC therapy. This respiratory rate and oxygenation (ROX) index is based on the traditional  $\text{PaO}_2/\text{F}_i\text{O}_2$  ratio, but is then coupled with the respiratory rate.<sup>23,25</sup> For practical bedside use,  $\text{PaO}_2$  is substituted for  $\text{SpO}_2$ , so the ROX index is defined as the  $([\text{SpO}_2/\text{F}_i\text{O}_2]/\text{respiratory rate})$ . It can be calculated using an online tool ([https://qxmd.com/calculate/calculator\\_724/rox-index-to-predict-risk-of-intubation](https://qxmd.com/calculate/calculator_724/rox-index-to-predict-risk-of-intubation)).

As an example, a patient with an  $\text{SpO}_2$  of 80%, an  $\text{F}_i\text{O}_2$  of 0.8, and an respiratory rate of 35/min  $([80/0.8]/35)$  will have a ROX index of 2.8. As the respiratory condition deteriorates, the ROX index decreases.

Roca *et al.* have suggested various ROX index cut-off values that are associated with the need for intubation.<sup>23</sup> Values below 2.85, 3.47, and 3.85 are the cut-off values used at two, six, and twelve hour, respectively. No predictive index is perfect, and a gray zone obviously exists between 3.85 and 4.88, in which it is difficult to firmly conclude what the optimal management should be. However, monitoring the ROX index over time, with emphasis from the 12th hour onwards, suggests that if the ROX index is  $\geq 4.88$ , then the patient has a high chance of avoiding intubation. If the ROX index is  $< 3.85$ , then the risk of HFNC failure is high. In the initial study of the ROX index<sup>23</sup> among patients in this zone, the ROX index



**Fig. 4** Computed tomographic and lung ultrasound correlation in a COVID-19 patient with subpleural consolidation. (Courtesy of Dr. Stéphan Langevin and Mr. Jacques Cadorette) (Video 4 available as Electronic Supplementary Material)

could be repeated one or two hours later. If the score has increased, the patient should be considered with a higher likelihood of avoiding intubation. If it has decreased, then intubation has a higher likelihood to be necessary. If the score is unchanged, then reassessment should be performed after one or two more hours. The ROX index has recently been implemented by one of the authors (N.P.) and is being considered, along with advice from other experts in mechanical ventilation, by the French Ministry of Health, who have arbitrarily decided to re-assess the ROX index every 30 min.<sup>26</sup> They have chosen a change in the ROX index of 0.5 to monitor the rapid onset of symptoms in the average COVID-19 patient compared with the usual ARDS patient. Therefore, a reduction of the ROX index by 0.5 from baseline over 30 min is considered significant and may suggest imminent need for intubation.<sup>23,25,26</sup> Indeed, such a strategy obviously requires a prospective evaluation.


### Role of lung ultrasound monitoring

Following the initiation of mechanical ventilation, it becomes important to discriminate between type-L vs type-H ARDS phenotypes for proper ventilator strategies

as proposed by Marini *et al.*<sup>27</sup> This is where lung ultrasound can be useful.

The sensitivity and specificity of lung ultrasound findings for COVID-19 remains to be determined. Nevertheless, based on several case series,<sup>7,8,28-30</sup> editorials/commentaries,<sup>9,10,31-35</sup> a recent narrative review,<sup>36</sup> and the authors own experience, four basic ultrasound patterns can be observed: 1) normal pattern (A lines and < 3 B-lines); 2) mild disease:  $\geq 3$  B-lines with some of them being confluent (waterfall or beam like)<sup>34</sup> (Fig. 3A) and thickened pleura suggestive of an L-type; 3) broken pleural lines (Fig. 3B) with B-lines; and 4) severe disease with subpleural consolidation (Fig. 3C,3D) and a typical ARDS picture.

The fourth pattern is more suggestive of an H-type. In H-type, ultrasound examination will often reveal some L-type features, such as loss of aeration and overlapping areas of peripheral or subpleural consolidation (Fig. 3C-F and Fig. 4), but pathological lesions will mostly be seen in the posterior region of the lung.<sup>7,30</sup> Management and triage would be different in patients with more extensive disease. Nevertheless, it is possible that the extent of any abnormal lung ultrasound pattern might be more important than the actual pattern or type of pathology itself. A large number of abnormal regions would correlate with the severity of lung



**Fig. 5** Examples of various COVID-19 complications detected using bedside ultrasound. Pulmonary hypertension with a trans-tricuspid pressure gradient (PG) of 45 mmHg in a patient developing right ventricular failure. B) Transthoracic short-axis aortic valve view showing a dilated right ventricular outflow tract (RVOT) of 35 mm and pulmonary artery in a patient with pulmonary embolism. C) Deep venous thrombosis of the femoral vein. D) Abnormal hepatic venous


flow (HVf) Doppler velocity suggestive of right ventricular diastolic dysfunction.<sup>71</sup> E) Renal venous congestion pattern-II associated with right ventricular dysfunction.<sup>71,72</sup> F) Enlarged optic nerve sheath (ONS)<sup>73,74</sup> in a patient with severe encephalopathy and extra-pyramidal signs. (Courtesy of Dr. Caroline Gebhard and Stéphan Langevin.). AR = atrial reversal HVf; D = diastolic HVf; S = systolic HVf. (Video 5B, 5C available as Electronic Supplementary Material.)

inflammation. Pleural effusions have been uncommonly observed<sup>7,32</sup> and were present in only 4.7% of patients in a series by Lomoro *et al.*<sup>28</sup> and in 10% of patients in a separate report by Xing *et al.*<sup>30</sup> The reduction or absence of a vascular Doppler signal in the areas of peripheral or subpleural consolidation (Fig. 1D,1F) is common in COVID-19<sup>7</sup> and could represent peripheral segmental lung infarction through a microangiopathy, as described recently by autopsies from the United States.<sup>37</sup> Coronavirus disease could be associated with an increased incidence of thrombotic complications such as pulmonary embolism.<sup>38-41</sup>

Standardization of lung ultrasound examination using a 14-region approach in COVID-19 has been recently proposed by Soldati *et al.*<sup>33</sup> This would allow both diagnostic and daily monitoring of the pulmonary lesions.<sup>42</sup> A simpler approach using six zones has also been recently proposed.<sup>43</sup> The relevance of serial lung ultrasound has previously been reported in a small series of patients with ARDS<sup>42</sup> unrelated to the current COVID-19 pandemic but the various scoring systems would need comparing and validating in COVID-19 patients. In that study, the non-resolution of pulmonary lesions was associated with worse outcome.<sup>42</sup>

As with any patients in the intensive care unit, COVID-19 patients can also develop other pulmonary complications. These include superimposed bacterial pneumonia, cardiogenic pulmonary edema related to myocardial dysfunction, right ventricular dysfunction and pulmonary hypertension due to pulmonary embolism, pleural effusions, and pneumothoraces.<sup>44,45</sup> As suggested by Volpicelli *et al.*, the bilateral patchy distribution of multiform clusters, alternating with “spared areas” is typical of the disease. Any other ultrasound signs should be considered at intermediate probability and should lead to further testing.<sup>34</sup>

Bedside ultrasound could be useful in detecting associated pulmonary complications or non-pulmonary complications such as cardiac dysfunction that can occur in such patients.<sup>46</sup> Combining heart, lung, deep veins examination<sup>41</sup> and whole-body ultrasound<sup>47,48</sup> can identify the mechanism,<sup>49</sup> risk factors,<sup>50</sup> and life-threatening conditions in patients with respiratory symptoms (Fig. 5).<sup>51</sup> Lung ultrasound can also impact clinical decision-making in patients with acute respiratory failure<sup>52,53</sup> and provide comprehensive monitoring of regional lung aeration changes that could be used to predict response to prone positioning with improved right



**Fig. 6** Lung ultrasound examination in a COVID-19 patient with severe hypoxia, before (A–C) and after (D–F) prone positioning. Note the significant changes with loss of pleural fluid and consolidation with increased aeration. Oxygen requirement was significantly reduced from 100% inspired oxygen to 60% for an adequate

oxygen saturation after proning. RLPAL = right lower posterior axillary line; RMPAL = right middle posterior axillary line; RUPAL = right upper posterior axillary line. (Courtesy of Dr. Stéphan Langevin.) (Videos 6A, 6B, 6C, 6D, 6E, and 6F available as Electronic Supplementary Material.)

ventricular function (Figs 6 and 7)<sup>54–56</sup> or higher positive end-expiratory pressure strategy.<sup>57</sup> Newer modalities such as strain and speckle tracking could eventually be used to detect early abnormal peripheral pulmonary stress.<sup>58,59</sup> The authors strongly advocate ultrasound as the key to rapid repeated progress imaging (rather than CT, which is more expensive and has logistical difficulties) and hence a decision to intubate would clearly be influenced by a rapidly deteriorating set of ultrasound images.

Repeated ultrasound imaging over time can allow for accurate determination of the progression of lung pathology and can strongly influence a decision to institute early mechanical ventilation. Such repeated ultrasound imaging would be logistically convenient at the bedside without transporting the patient to the radiology department and would not involve any radiation dosing. Nevertheless, although lung ultrasound outperforms chest radiograph,<sup>60,61</sup> it cannot be as comprehensive as CT since any lung pathology not involving the surface of the lung (and therefore covered by some aerated lung) cannot be detected by ultrasound. Lung ultrasound can be performed with a wide range of ultrasound machines, including handheld devices.<sup>62</sup> The advantage of the handheld devices is that they can be fully enclosed in a plastic sheath, thereby reducing the risk of equipment contamination and spread of infection between


patients. The performance and interpretation of lung ultrasound is much simpler than other imaging modalities such as transthoracic echocardiography as the images are easy to acquire and there are a limited number of patterns to interpret.<sup>63,64</sup> Education can be scaled to meet the COVID-19 crisis through online courses (e.g., <https://www.iteachu.com/courses/covid-19-lung-ultrasound/>) simulation, and peer-to-peer mentoring.

### Other management modalities and limitations

Other important elements in deciding whether to intubate is the work of breathing.<sup>27</sup> This can also be monitored clinically by observing the use of accessory muscles or by measuring or estimating changes in pleural pressure.<sup>13</sup> Once mechanical ventilation is initiated, tidal volume, respiratory rate, positive-pressure ventilation, prone positioning and veno-venous extracorporeal membrane oxygenation, sedation, and neuromuscular blockade will be adjusted differently depending on the phenotype and in accordance to ARDS management guidelines.<sup>65–68</sup>

Finally, there are still several unanswered questions and uncertainties regarding COVID-19 respiratory infections and the role of bedside ultrasound. We are still on an





**Fig. 7** Cardiac examination and portal vein interrogation before (A–B) and after (C–D) prone positioning. Note the reduction in the size of the right ventricle (RV) in relation to the left ventricle (LV) and the

improved portal velocities and reduction in the portal vein pulsatility index (PVPI). (Courtesy of Dr. Stéphan Langevin.) (Videos 7A and 7C available as Electronic Supplementary Material.)

**Table** Undetermined issues in the respiratory complications and use of lung ultrasound in COVID-19 patients

- 1) What are the sensitivity and specificity of the ultrasound findings in determining the severity and type of lung disease phenotypes?
- 2) What is the sensitivity and specificity of the ROX index in predicting requirement for intubation and how does it correlate with ultrasound findings?
- 3) What is the mechanism of hypoxia in the early phase or L-type phenotype?
- 4) What are the performances of the various lung ultrasound scoring systems?
- 5) What are the role of the new modalities such as strain and speckle tracking in detecting early abnormal peripheral pulmonary stress?
- 6) What are the case-based or population-based outcomes related to specific lung ultrasound findings?
- 7) Can we determine response to prone positioning with lung ultrasound?
- 8) Does the routine use of lung ultrasound improve the care of COVID-19 patients?
- 9) What is the outcome of a different lung strategy with or without lung ultrasound for the L-type and H-type phenotypes?

COVID-19 = coronavirus disease; ROX = respiratory rate and oxygenation

ascending learning curve regarding this new medical condition. Our proposed algorithm, which reflects the current understanding of COVID-19 respiratory failure, is likely to evolve as new information becomes available. The Table summarizes key questions on respiratory

complications and management in COVID-19 patients with the use of lung ultrasound.

Our understanding of COVID-19 and its effect on the respiratory system is rapidly evolving. Biochemical pathways involving cardiovascular issues have recently been described by Liu *et al.*<sup>46</sup> This novel knowledge might

contribute to understanding more about the two suggested phenotypes described by Gattinoni *et al.*<sup>11,13</sup> It might also be used to confirm or challenge the aforementioned phenotypes categorization.<sup>69,70</sup> Bedside lung ultrasound can help identify severity of lung involvement and response to therapy, as part of evaluation for ventilation as well as during the recovery and weaning process. With the implementation of this emerging information, clinical management may be somewhat distinct from that of other evidence-based interventions. As a result, clinical trials will be required to determine the best ventilation strategies for the different lung-involvement phenotypes seen in hypoxic COVID-19 patients.

**Author contributions** André Y. Denault, Stéphane Delisle, Stéphan Langevin, and Paul Ouellet contributed to all aspects of this manuscript, including study conception and design; acquisition, analysis, and interpretation of data; and drafting the article. David Canty, Alistair Royse, Colin Royse, Ximena Cid Serra, Caroline E. Gebhard, Etienne J. Couture, Martin Girard, Yiorgos Alexandros Cavayas, and Nicolas Peschanski contributed to study conception and design, and interpretation of data.

**Disclosure** Dr. Denault is on the speakers bureau for CAE Healthcare (2010), Masimo (2017) and received an equipment grant from Edwards (2019).

**Funding statement** Supported by the Richard I. Kaufman Endowment Fund in Anesthesia and Critical Care and the Montreal Heart Institute Foundation. The funding body had no role in the design of study and collection, analysis, and interpretation of data and in writing of the manuscript.

**Editorial responsibility** This submission was handled by Dr. Hilary P. Grocott, Editor-in-Chief, *Canadian Journal of Anesthesia*.

## References

- Zhu N, Zhang D, Wang W, *et al.* A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med* 2020; 382: 727-33.
- Guan WJ, Ni ZY, Hu Y, *et al.* Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020; DOI: <https://doi.org/10.1056/NEJMoa2002032>.
- CDC COVID-19 Response Team. Geographic differences in COVID-19 cases, deaths, and incidence - United States, February 12-April 7, 2020. *MMWR Morb Mortal Wkly Rep* 2020; 69: 465-71.
- Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. *JAMA* 2020; DOI: <https://doi.org/10.1001/jama.2020.4683>.
- Chen R, Chen J, Meng QT. Chest computed tomography images of early coronavirus disease (COVID-19). *Can J Anesth* 2020; DOI: <https://doi.org/10.1007/s12630-020-01625-4>.
- Wong HY, Lam HY, Fong AH, *et al.* Frequency and distribution of chest radiographic findings in COVID-19 positive patients. *Radiology* 2019; DOI: <https://doi.org/10.1148/radiol.2020201160>.
- Huang Y, Wang S, Liu Y, *et al.* A preliminary study on the ultrasonic manifestations of peripulmonary lesions of non-critical novel coronavirus pneumonia (COVID-19). *Research Square Preprint*. Available from URL: [https://www.researchgate.net/publication/340198841\\_A\\_preliminary\\_study\\_on\\_the\\_ultrasonic\\_manifestations\\_of\\_peripulmonary\\_lesions\\_of\\_non-critical\\_novel\\_coronavirus\\_pneumonia\\_COVID-19/fulltext/5e7ce451a6fdcc139c08b101/340198841\\_A\\_preliminary\\_study\\_on\\_the\\_ultrasonic\\_manifestations\\_of\\_peripulmonary\\_lesions\\_of\\_non-critical\\_novel\\_coronavirus\\_pneumonia\\_COVID-19.pdf?origin=publication\\_detail](https://www.researchgate.net/publication/340198841_A_preliminary_study_on_the_ultrasonic_manifestations_of_peripulmonary_lesions_of_non-critical_novel_coronavirus_pneumonia_COVID-19/fulltext/5e7ce451a6fdcc139c08b101/340198841_A_preliminary_study_on_the_ultrasonic_manifestations_of_peripulmonary_lesions_of_non-critical_novel_coronavirus_pneumonia_COVID-19.pdf?origin=publication_detail) (accessed May 2020).
- Peng QY, Wang XT, Zhang LN; Chinese Critical Care Ultrasound Study Group. Findings of lung ultrasonography of novel corona virus pneumonia during the 2019-2020 epidemic. *Intensive Care Med* 2020; DOI: <https://doi.org/10.1007/s00134-020-05996-6>.
- Poggiali E, Dacrema A, Bastoni D, *et al.* Can lung US help critical care clinicians in the early diagnosis of novel coronavirus (COVID-19) pneumonia? *Radiology* 2020; DOI: <https://doi.org/10.1148/radiol.2020200847>.
- Soldati G, Smargiassi A, Inchingolo R, *et al.* Is there a role for lung ultrasound during the COVID-19 pandemic? *J Ultrasound Med* 2020; DOI: <https://doi.org/10.1002/jum.15284>.
- Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. Covid-19 does not lead to a “typical” acute respiratory distress syndrome. *Am J Respir Crit Care Med* 2020; DOI: <https://doi.org/10.1164/rccm.202003-0817LE>.
- Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? *Crit Care* 2020; DOI: <https://doi.org/10.1186/s13054-020-02880-z>.
- Gattinoni L, Chiumello D, Caironi P, *et al.* COVID-19 pneumonia: different respiratory treatment for different phenotypes? *Intensive Care Med* 2020; DOI: <https://doi.org/10.1007/s00134-020-06033-2>.
- Barach AL, Martin J, Eckman M. Positive pressure respiration and its application to the treatment of acute pulmonary edema. *Ann Intern Med* 1938; 12: 754-95.
- Mascheroni D, Kolobow T, Fumagalli R, Moretti MP, Chen V, Buckhold D. Acute respiratory failure following pharmacologically induced hyperventilation: an experimental animal study. *Intensive Care Med* 1988; 15: 8-14.
- Brochard L, Slutsky A, Pesenti A. Mechanical ventilation to minimize progression of lung injury in acute respiratory failure. *Am J Respir Crit Care Med* 2017; 195: 438-42.
- Grieco DL, Menga LS, Eleuteri D, Antonelli M. Patient self-inflicted lung injury: implications for acute hypoxemic respiratory failure and ARDS patients on non-invasive support. *Minerva Anestesiol* 2019; 85: 1014-23.
- Yoshida T, Grieco DL, Brochard L, Fujino Y. Patient self-inflicted lung injury and positive end-expiratory pressure for safe spontaneous breathing. *Curr Opin Crit Care* 2020; 26: 59-65.
- Nuckton TJ, Alonso JA, Kallet RH, *et al.* Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndrome. *N Engl J Med* 2002; 346: 1281-6.
- Wang Y, Dong C, Hu Y, *et al.* Temporal changes of CT findings in 90 patients with COVID-19 pneumonia: a longitudinal study. *Radiology* 2020; DOI: <https://doi.org/10.1148/radiol.2020200843>.
- Pan F, Ye T, Sun P, *et al.* Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. *Radiology* 2020; DOI: <https://doi.org/10.1148/radiol.2020200370>.
- Covelli HD, Nesson VJ, Tuttle WK 3rd. Oxygen derived variables in acute respiratory failure. *Crit Care Med* 1983; 11: 646-9.
- Roca O, Messika J, Caralt B, *et al.* Predicting success of high-flow nasal cannula in pneumonia patients with hypoxemic

- respiratory failure: the utility of the ROX index. *J Crit Care* 2016; DOI: <https://doi.org/10.1016/j.jcrc.2016.05.022>.
24. *Cinesi Gomez C, Penuelas Rodriguez O, Lujan Torne M, et al.* Clinical consensus recommendations regarding non-invasive respiratory support in the adult patient with acute respiratory failure secondary to SARS-CoV-2 infection. *Med Intensiva* 2020; DOI: <https://doi.org/10.1016/j.medin.2020.03.005>.
  25. *Roca O, Caralt B, Messika J, et al.* An index combining respiratory rate and oxygenation to predict outcome of nasal high-flow therapy. *Am J Respir Crit Care Med* 2019; 199: 1368-76.
  26. *Ministere des Solidarites et de la Sante Direction Generale de la Sante Centre de Crise Sanitaire.* Doctrine d'usage des dispositifs de ventilation et des respirateurs pour les patients COVID-19. Available from URL: [https://www.reulian.fr/app/download/24477393/Message\\_MARS\\_2020\\_27\\_8791\\_9.pdf](https://www.reulian.fr/app/download/24477393/Message_MARS_2020_27_8791_9.pdf) (accessed May 2020).
  27. *Marini JJ, Gattinoni L.* Management of COVID-19 respiratory distress. *JAMA* 2020; DOI: <https://doi.org/10.1001/jama.2020.6825>.
  28. *Lomoro P, Verde F, Zerboni F, et al.* COVID-19 pneumonia manifestations at the admission on chest ultrasound, radiographs, and CT: single-center study and comprehensive radiologic literature review. *Eur J Radiol Open* 2020; DOI: <https://doi.org/10.1016/j.ejro.2020.100231>.
  29. *Lu W, Zhang S, Chen B, et al.* A clinical study of noninvasive assessment of lung lesions in patients with coronavirus disease-19 (COVID-19) by bedside ultrasound. *Ultraschall Med* 2020; DOI: <https://doi.org/10.1055/a-1154-8795>.
  30. *Xing C, Li Q, Du H, Kang W, Lian J, Yuan L.* Lung ultrasound findings in patients with COVID-19 pneumonia. *Crit Care* 2020; DOI: <https://doi.org/10.1186/s13054-020-02876-9>.
  31. *Moore S, Gardiner E.* Point of care and intensive care lung ultrasound: a reference guide for practitioners during COVID-19. *Radiography* 2020; DOI: <https://doi.org/10.1016/j.radi.2020.04.005>.
  32. *Sofia S, Boccatonda A, Montanari M, et al.* Thoracic ultrasound and SARS-COVID-19: a pictorial essay. *J Ultrasound* 2020; DOI: <https://doi.org/10.1007/s40477-020-00458-7>.
  33. *Soldati G, Smargiassi A, Inchingolo R, et al.* Proposal for international standardization of the use of lung ultrasound for patients with COVID-19: a simple, quantitative, reproducible method. *J Ultrasound Med* 2020; DOI: <https://doi.org/10.1002/jum.15285>.
  34. *Volpicelli G, Gargani L.* Sonographic signs and patterns of COVID-19 pneumonia. *Ultrasound J* 2020; DOI: <https://doi.org/10.1186/s13089-020-00171-w>.
  35. *Vetrugno L, Bove T, Orso D, et al.* Our Italian experience using lung ultrasound for identification, grading and serial follow-up of severity of lung involvement for management of patients with COVID-19. *Echocardiography* 2020; 37: 625-7.
  36. *Smith MJ, Hayward SA, Innes SM, Miller AS.* Point-of-care lung ultrasound in patients with COVID-19 - a narrative review. *Anaesthesia* 2020; DOI: <https://doi.org/10.1111/anae.15082>.
  37. *Fox SE, Akmatbekov A, Harbert JL, Li G, Brown JQ, Vander Heide RS.* Pulmonary and cardiac pathology in covid-19: the first autopsy series from New Orleans. medRxiv preprint. 2020; DOI: <https://doi.org/10.1101/2020.04.06.20050575>.
  38. *Leonard-Lorant I, Delabranche X, Severac F, et al.* Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship to D-dimer levels. *Radiology* 2020; DOI: <https://doi.org/10.1148/radiol.2020201561>.
  39. *Klok FA, Kruip MJ, van der Meer NJ, et al.* Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res* 2020; DOI: <https://doi.org/10.1016/j.thromres.2020.04.013>.
  40. *Ullah W, Saeed R, Sarwar U, Patel R, Fischman DL.* COVID-19 complicated by acute pulmonary embolism and right-sided heart failure. *JACC Case Rep* 2020; DOI: <https://doi.org/10.1016/j.jaccas.2020.04.008>.
  41. *Tavazzi G, Civaridi L, Caneva L, Mongodi S, Mojoli F.* Thrombotic events in SARS-CoV-2 patients: an urgent call for ultrasound screening. *Intensive Care Med* 2020; DOI: <https://doi.org/10.1007/s00134-020-06040-3>.
  42. *Mongodi S, Pozzi M, Orlando A, et al.* Lung ultrasound for daily monitoring of ARDS patients on extracorporeal membrane oxygenation: preliminary experience. *Intensive Care Med* 2018; 44: 123-4.
  43. *Cid X, Canty D, Royse A, et al.* Impact of point-of-care ultrasound on the hospital length of stay for internal medicine inpatients with cardiopulmonary diagnosis at admission: study protocol of a randomized controlled trial-the IMFCU-1 (Internal Medicine Focused Clinical Ultrasound) study. *Trials* 2020; DOI: <https://doi.org/10.1186/s13063-019-4003-2>.
  44. *Lichtenstein DA, Menu Y.* A bedside ultrasound sign ruling out pneumothorax in the critically ill. *Lung sliding*. *Chest* 1995; 108: 1345-8.
  45. *Alrajab S, Youssef AM, Akkus NI, Caldito G.* Pleural ultrasonography versus chest radiography for the diagnosis of pneumothorax: review of the literature and meta-analysis. *Crit Care* 2013; DOI: <https://doi.org/10.1186/cc13016>.
  46. *Liu PP, Blet A, Smyth D, Li H.* The science underlying COVID-19: implications for the cardiovascular system. *Circulation* 2020; DOI: <https://doi.org/10.1161/CIRCULATIONAHA.120.047549>.
  47. *Karabinis A, Fragou M, Karakitsos D.* Whole-body ultrasound in the intensive care unit: a new role for an aged technique. *J Crit Care* 2010; 25: 509-13.
  48. *Denault A, Canty D, Azzam M, Amir A, Gebhard CE.* Whole body ultrasound in the operating room and the intensive care unit. *Korean J Anesthesiol* 2019; DOI: <https://doi.org/10.4097/kja.19186>.
  49. *Sekiguchi H, Schenck LA, Horie R, et al.* Critical care ultrasonography differentiates ARDS, pulmonary edema, and other causes in the early course of acute hypoxemic respiratory failure. *Chest* 2015; 148: 912-8.
  50. *Kory PD, Pellicchia CM, Shiloh AL, Mayo PH, DiBello C, Koenig S.* Accuracy of ultrasonography performed by critical care physicians for the diagnosis of DVT. *Chest* 2011; 139: 538-42.
  51. *Laursen CB, Sloth E, Lambrechtsen J, et al.* Focused sonography of the heart, lungs, and deep veins identifies missed life-threatening conditions in admitted patients with acute respiratory symptoms. *Chest* 2013; 144: 1868-75.
  52. *Silva S, Biendel C, Ruiz J, et al.* Usefulness of cardiothoracic chest ultrasound in the management of acute respiratory failure in critical care practice. *Chest* 2013; 144: 859-65.
  53. *Xirouchaki N, Kondili E, Prinianakis G, Malliotakis P, Georgopoulos D.* Impact of lung ultrasound on clinical decision making in critically ill patients. *Intensive Care Med* 2014; 40: 57-65.
  54. *Vieillard-Baron A, Charron C, Caille V, Belliard G, Page B, Jardin F.* Prone positioning unloads the right ventricle in severe ARDS. *Chest* 2007; 132: 1440-6.
  55. *Prat G, Guinard S, Bizien N, et al.* Can lung ultrasonography predict prone positioning response in acute respiratory distress syndrome patients? *J Crit Care* 2016; 32: 36-41.
  56. *Haddam M, Zieleskiewicz L, Perbet S, et al.* Lung ultrasonography for assessment of oxygenation response to prone position ventilation in ARDS. *Intensive Care Med* 2016; 42: 1546-56.
  57. *Bouhemad B, Brisson H, Le-Guen M, Arbelot C, Lu Q, Rouby JJ.* Bedside ultrasound assessment of positive end-expiratory

- pressure-induced lung recruitment. *Am J Respir Crit Care Med* 2011; 183: 341-7.
58. Rubin JM, Horowitz JC, Sisson TH, Kim K, Ortiz LA, Hamilton JD. Ultrasound strain measurements for evaluating local pulmonary ventilation. *Ultrasound Med Biol* 2016; 42: 2525-31.
59. Duclos G, Bobbia X, Markarian T, et al. Speckle tracking quantification of lung sliding for the diagnosis of pneumothorax: a multicentric observational study. *Intensive Care Med* 2019; 45: 1212-8.
60. Lichtenstein D, Goldstein I, Mourgeon E, Cluzel P, Grenier P, Rouby JJ. Comparative diagnostic performances of auscultation, chest radiography, and lung ultrasonography in acute respiratory distress syndrome. *Anesthesiology* 2004; 100: 9-15.
61. Tierney DM, Huelster JS, Overgaard JD, et al. Comparative performance of pulmonary ultrasound, chest radiograph, and CT among patients with acute respiratory failure. *Crit Care Med* 2020; 48: 151-7.
62. Sforza A, Mancusi C, Carlino MV, et al. Diagnostic performance of multi-organ ultrasound with pocket-sized device in the management of acute dyspnea. *Cardiovasc Ultrasound* 2017; DOI: <https://doi.org/10.1186/s12947-017-0105-8>.
63. See KC, Ong V, Wong SH, et al. Lung ultrasound training: curriculum implementation and learning trajectory among respiratory therapists. *Intensive Care Med* 2016; 42: 63-71.
64. Ford JW, Heiberg J, Brennan AP, et al. A Pilot assessment of 3 point-of-care strategies for diagnosis of perioperative lung pathology. *Anesth Analg* 2017; 124: 734-42.
65. *Acute Respiratory Distress Syndrome Network*; Brower RG, Matthay MA, et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med* 2000; 342: 1301-8.
66. Malhotra A. Low-tidal-volume ventilation in the acute respiratory distress syndrome. *N Engl J Med* 2007; 357: 1113-20.
67. Mercat A, Richard JC, Vielle B, et al. Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. *JAMA* 2008; 299: 646-55.
68. Amato MB, Meade MO, Slutsky AS, et al. Driving pressure and survival in the acute respiratory distress syndrome. *N Engl J Med* 2015; 372: 747-55.
69. Ziehr DR, Alladina J, Petri CR, et al. Respiratory pathophysiology of mechanically ventilated patients with COVID-19: a cohort study. *Am J Respir Crit Care Med* 2020; DOI: <https://doi.org/10.1164/rccm.202004-1163LE>.
70. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle region - case series. *N Engl J Med* 2020; DOI: <https://doi.org/10.1056/NEJMoa2004500>.
71. Beaubien-Souligny W, Rola P, Haycock K, et al. Quantifying systemic congestion with point-of-care ultrasound: development of the venous excess ultrasound grading system. *Ultrasound J* 2020; DOI: <https://doi.org/10.1186/s13089-020-00163-w>.
72. Beaubien-Souligny W, Denault A, Robillard P, Desjardins G. The role of point-of-care ultrasound monitoring in cardiac surgical patients with acute kidney injury. *J Cardiothorac Vasc Anesth* 2019; 33: 2781-96.
73. Robba C, Goffi A, Geeraerts T, et al. Brain ultrasonography: methodology, basic and advanced principles and clinical applications. A narrative review. *Intensive Care Med* 2019; DOI: <https://doi.org/10.1007/s00134-019-05610-4>.
74. Palermo J, Bojanowski M, Langevin S, Denault AY. Point-of-care handheld ophthalmic ultrasound in the diagnosis and evaluation of raised intracranial pressure and Terson syndrome: a description of two cases. *Can J Anesth* 2020; 67: 353-9.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.